Expansion of stem cells in hollow fiber bioreactors

Hollow fiber bioreactors with controlled nutrient and waste management systems address the challenges of high-density cell expansion and microenvironment maintenance, enabling efficient amplification and differentiation of non-embryonic stem cells for clinical use.

JP2024164160AInactive Publication Date: 2024-11-26レゲネシスベーフェー
View PDF 48 Cites 0 Cited by

Patent Information

Application Number
JP2024141871
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2011-06-06
Filing Date
2024-08-23
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing hollow fiber bioreactor technologies face challenges in achieving high-density cell expansion and maintaining a suitable microenvironment for cell culture, particularly in clinical applications, due to limitations in nutrient diffusion and waste removal as cell layers thicken, and require improvements in lattice materials and continuous medium exchange.

Method used

The use of hollow fiber continuous perfusion bioreactors with controlled nutrient supply and waste removal systems, allowing for the expansion of non-embryonic, stem, non-reproductive cells with high purity and differentiation potential, using fibers with specific design parameters such as pore size, wall thickness, and material composition to support cell attachment and growth.

Benefits of technology

This approach enables the amplification of cells up to 1000 times their original number while maintaining a normal karyotype and pluripotency markers, facilitating their differentiation into multiple cell types without transformation, and supports co-culture with other cell types for enhanced clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164160000001
    Figure 2024164160000001
  • Figure 2024164160000002
    Figure 2024164160000002
  • Figure 2024164160000003
    Figure 2024164160000003
Patent Text Reader

Abstract

To provide producing large numbers of cells using hollow fiber bioreactor technology.SOLUTION: The cells are non-embryonic, stem, and non-germ cells that can be characterized by one or more of the following: an expanded replication in a culture and a marker of the expanded replication without being transformed, such as a telomerase, a pluripotential marker, and a broad differentiation potential. For example, provided is a method of expanding cells ex vivo, which comprises steps of: a) seeding the cells on a hollow fiber substrate so that the cells adhere to the substrate; b) expanding the adhered cells on the substrate; and c) removing the expanded cells from the substrate, in which the cells are non-embryonic, stem, and non-germ cells, express telomerase, are not transformed, and have a normal karyotype.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to the use of hollow fiber continuous perfusion bioreactor technology to produce large numbers of non-embryonic, stem, non-reproductive cells that can be characterized by one or more of the following: amplified replication in culture without transformation and markers of amplified replication, such as telomerase, pluripotentiality markers, and a wide range of differentiation potential. [Background technology]

[0002] 2. Background of the Invention Hollow fiber bioreactor technology has been used to obtain high density cell expansion. Typically, cells are expanded inside and / or outside of a number of hollow fibers. Due to the large surface area provided by this design, the use of the fibers as a culture substrate allows the production of large numbers of cells (especially for clinical use). The technology was first developed by Knazek in the 1970s and has undergone numerous developments and improvements. The basic concept is to provide a fiber matrix that is permeable to nutrients, gases and other basic medium components, as well as cellular waste products, but impermeable to cells, in which said cells can expand.

[0003] Cell culture in semi-permeable tubular membranes was first invented by Knazek in the early 1970s. See, for example, U.S. Pat. No. 3,821,087; U.S. Pat. No. 3,883,393; U.S. Pat. No. 4,220,725; U.S. Pat. No. 4,184,922; and U.S. Pat. No. 4,200,689. Based on that invention, cells suspended in nutrient medium were settled on the outer surface of a capillary that was continuously perfused with oxygenated nutrient medium flowing through the capillary. Nutrients diffused from the perfusion medium through the capillary wall into the cells, while cellular waste products diffused from the cells through the capillary wall into the perfusate from which their products could be recovered.

[0004] The technology was developed as a response to failed attempts to grow cells to a density and / or structure approaching that of living tissues. There were mainly problems in growing viable cells to very high densities as found in tissues. First, medium components must diffuse through the cell layer to reach all cells even as the cell layer thickness increases. Second, a suitable microenvironment must be maintained in the cell culture. For this, the fluid in the immediate vicinity of the growing cells is continuously exchanged as the cell metabolism progresses, and is restored only in a stepwise manner when the culture medium is exchanged or agitated. Third, a lattice or suitable material on which to grow high densities of cells is required. Knazek's invention solved these problems by providing a nutrient source within the cell mass that provides both large and small essential molecules; a sink within the cell mass to remove metabolic products; a suitable microenvironment; a lattice that allows growth in three dimensions; and a large surface area for monolayer and / or multilayer cell culture compared to the volumes required by standard cell culture techniques.

[0005] Since the original invention, this technology has been used successfully to amplify a variety of cell types. There is a large body of scientific and patent literature on various refinements of this basic technology. These refinements have addressed various technical modifications to optimize the use of this technology to achieve Knazek's original objectives. In the industry, this technology has come to be named "hollow fiber" cell culture, and in a bioreactor setting, hollow fiber bioreactor cell culture is provided.For example, Patent Documents 6 to 48 (U.S. Patent No. 3,997,396; U.S. Patent No. 4,184,922; U.S. Patent No. 4,200,689; U.S. Patent No. 4,220,725; U.S. Patent No. 4,804,628; U.S. Patent No. 4,999,298; U.S. Patent No. 5,126,238; U.S. Patent No. 5,162,225; U.S. Patent No. 5,627,070; U.S. Patent No. 5,656,421; U.S. Patent No. 5,712,154; U.S. Patent No. 6,001,585; U.S. Patent No. 6, 680,166; U.S. Patent No. 6,911,201; U.S. Patent No. 6,933,144; U.S. Patent No. 7,534,609; U.S. Patent Application Publication No. 2001 / 0044413; U.S. Patent Application Publication No. 2003 / 0224510; U.S. Patent Application Publication No. 2005 / 0032218; U.S. Patent Application Publication No. 2005 / 0003530; U.S. Patent Application Publication No. 2006 / 0205071; U.S. Patent Application Publication No. 2007 / 0298497; U.S. Patent Application Publication No. 2008 / 0206733 No.;U.S. Patent Application Publication No. 2008 / 0213894;U.S. Patent Application Publication No. 2008 / 0220522;U.S. Patent Application Publication No. 2008 / 0220523;U.S. Patent Application Publication No. 2008 / 0227190;U.S. Patent Application Publication No. 2008 / 248572;U.S. Patent Application Publication No. 2008 / 254533;U.S. Patent Application Publication No. 2009 / 0191631;U.S. Patent Application Publication No. 2009 / 0196901;U.S. Patent Application Publication No. 2010 / 0042260;U.S. Patent Application Publication No. No. 2010 / 0144037; U.S. Patent Application Publication No. 2010 / 0209403; U.S. Patent Application Publication No. 2010 / 0233130; U.S. Patent Application Publication No. 2010 / 0267134; WO 91 / 18972; WO 95 / 13088; WO 95 / 21911; WO 01 / 23520; WO 07 / 012144; WO 10 / 034468; WO 10 / 149597; and non-patent literature 1 (Gloeckner et al., Biotech. Prog 17:828-31 (2001).

[0006] US Patent Publication No. 2010 / 0267134 discloses the isolation, characterization and differentiation of adult human germline stem cells using hollow fiber capillary culture. This reference describes the growth of spermatogonial stem cells on a feeder layer of Sertoli cells seeded on the surface of the hollow fiber capillary.

[0007] Patent document 50 (US Patent Application Publication No. 2007 / 0298497) and patent document 51 (US Patent Application Publication No. 2008 / 0220523) disclose hollow fiber bioreactor technology applied to mesenchymal stem cells. A cell expansion system and method for expanding mesenchymal stem cells using said technology are described.

[0008] US Patent Publication No. 2009 / 0196901 relates to a method and system for promoting the proliferation and differentiation of adipose-derived stem cells. The cells can be grown using a biologically compatible scaffold structure, which may include hollow fibers for cell proliferation and differentiation. The scaffold is cultured in a bioreactor for the proliferation and differentiation of the cells. The reference suggests that other stem cell types can be used for this process. However, the cells are already significantly amplified in cell culture before proliferation and differentiation on a woven fiber scaffold for culture in the bioreactor. This produces a sufficient number of stem cells so that the cells can be enriched and suspended in a matrix (e.g., a gel-like biomaterial) and applied to a three-dimensional scaffold.

[0009] US Patent Publication No. 2010 / 0209403 discloses a method for expanding attached placental and adipose mesenchymal stem cells in a bioreactor that may include hollow fibers.

[0010] WO 95 / 13088 discloses hollow fiber technology for expanding hematopoietic stem cells using stromal cell supports.

[0011] Patent document 55 (WO 91 / 18972) discloses a hollow fiber bioreactor for expanding bone marrow derived hematopoietic stem cells.

[0012] WO 07 / 012144 discloses a hollow fiber bioreactor for growing embryonic stem cells and other cells that is improved by attaching linkers to the surface.

[0013] WO 10 / 149597 discloses a hollow fiber bioreactor for growing spermatogonia and other cells of the germ line.

[0014] WO 10 / 034468 discloses a hollow fibre technology in which adherent cells are grown without a coating (eg mesenchymal stem cells).

[0015] Non-Patent Document 2 (Antwiler et al., "Bioreactor Design and "Ex vivo Expansion of Mesenchymal Stem Cells from Both Bone Marrow Mononuclear Cells and Whole Bone Marrow," Stem Cell Bioengineering, edited by Parekkadan and Yarmush, pp. 49-62 (2009), discloses a method for ex vivo expansion of mesenchymal stem cells from both bone marrow mononuclear cells and whole bone marrow using an automated hollow fiber bioreactor system. The system included a synthetic hollow fiber bioreactor connected to a sterile closed loop computer-controlled medium and gas exchanger. In an experimental setting, this allowed for the expansion of therapeutic doses of mesenchymal stem cells from a small single bone marrow aspirate in a relatively short period of time. [Prior art documents] [Patent documents]

[0016] [Patent Document 1] U.S. Pat. No. 3,821,087 [Patent Document 2] U.S. Pat. No. 3,883,393 [Patent Document 3] U.S. Pat. No. 4,220,725 [Patent Document 4] U.S. Pat. No. 4,184,922 [Patent Document 5] U.S. Pat. No. 4,200,689 [Patent Document 6] U.S. Pat. No. 3,997,396 [Patent Document 7] U.S. Pat. No. 4,184,922 [Patent Document 8] U.S. Pat. No. 4,200,689 [Patent Document 9] U.S. Pat. No. 4,220,725 [Patent Document 10] U.S. Pat. No. 4,804,628 [Patent Document 11] U.S. Pat. No. 4,999,298 [Patent Document 12] U.S. Pat. No. 5,126,238 [Patent Document 13] U.S. Patent No. 5,162,225 [Patent Document 14] U.S. Patent No. 5,627,070 [Patent Document 15] U.S. Pat. No. 5,656,421 [Patent Document 16] U.S. Pat. No. 5,712,154 [Patent Document 17] U.S. Patent No. 6,001,585 [Patent Document 18] U.S. Patent No. 6,680,166 [Patent Document 19] U.S. Patent No. 6,911,201 [Patent Document 20] U.S. Patent No. 6,933,144 [Patent Document 21] U.S. Pat. No. 7,534,609 [Patent Document 22] US Patent Application Publication No. 2001 / 0044413 [Patent Document 23] US Patent Application Publication No. 2003 / 0224510 [Patent Document 24] US Patent Application Publication No. 2005 / 0032218 [Patent Document 25] US Patent Application Publication No. 2005 / 0003530 [Patent Document 26] US Patent Application Publication No. 2006 / 0205071 [Patent Document 27] US Patent Application Publication No. 2007 / 0298497 [Patent Document 28] US Patent Application Publication No. 2008 / 0206733 [Patent Document 29] US Patent Application Publication No. 2008 / 0213894 [Patent Document 30] US Patent Application Publication No. 2008 / 0220522 [Patent Document 31] US Patent Application Publication No. 2008 / 0220523 [Patent Document 32] US Patent Application Publication No. 2008 / 0227190 [Patent Document 33] US Patent Application Publication No. 2008 / 248572 [Patent Document 34] US Patent Application Publication No. 2008 / 254533 [Patent Document 35] US Patent Application Publication No. 2009 / 0191631 [Patent Document 36] US Patent Application Publication No. 2009 / 0196901 [Patent Document 37] US Patent Application Publication No. 2010 / 0042260 [Patent Document 38] US Patent Application Publication No. 2010 / 0144037 [Patent Document 39] US Patent Application Publication No. 2010 / 0209403 [Patent Document 40] US Patent Application Publication No. 2010 / 0233130 [Patent Document 41] US Patent Application Publication No. 2010 / 0267134 [Patent Document 42] International Publication No. 91 / 18972 [Patent Document 43] International Publication No. 95 / 13088 [Patent Document 44] International Publication No. 95 / 21911 [Patent Document 45] International Publication No. 01 / 23520 [Patent Document 46] International Publication No. 07 / 012144 [Patent Document 47] International Publication No. 10 / 034468 [Patent Document 48] International Publication No. 10 / 149597 [Patent Document 49] US Patent Application Publication No. 2010 / 0267134 [Patent Document 50] US Patent Application Publication No. 2007 / 0298497 [Patent Document 51] US Patent Application Publication No. 2008 / 0220523 [Patent Document 52] US Patent Application Publication No. 2009 / 0196901 [Patent Document 53] US Patent Application Publication No. 2010 / 0209403 [Patent Document 54] WO 95 / 13088 [Patent Document 55] International Publication No. 91 / 18972 [Patent Document 56] International Publication No. 07 / 012144 [Patent Document 57] WO 10 / 149597 [Patent Document 58] WO 10 / 034468 [Non-patent literature]

[0017] [Non-Patent Document 1] Gloeckner et al., Biotech Prog 17:828-31 (2001) [Non-Patent Document 2] Antwiler et al. ("Bioreactor Design and Implementation," Stem Cell Bioengineering, eds. Parekkadan and Yarmush, pp. 49-62 (2009) Summary of the Invention [Means for solving the problem]

[0018] Summary of the Invention The present invention relates to expanding the cells described herein in hollow fiber bioreactors. Continuous perfusion for continuous nutrient supply and removal of waste metabolites is an aspect of the invention. Harvesting of desired secreted molecules is also an aspect.

[0019] The cells may be expanded directly from tissue samples, e.g., from bone marrow, umbilical cord blood, placenta, as a crude or partially purified preparation. Alternatively, the cells may be a purified cell preparation, which is substantially homogenous and has previously been isolated and expanded or otherwise purified. Thus, the purity of the starting cell preparation may be substantially crude (e.g., starting from total bone marrow mononuclear cells) or may be between 1% and 100% pure. In some embodiments, the purity of the cells for administration to a subject is about 100% (substantially homogenous). In other embodiments, the purity is between 95% and 100%. In some embodiments, the purity is between 85% and 95%. However, the percentage may be about 1%-5%, 5%-10%, 10%-15%, 15%-20%, 20%-25%, 25%-30%, 30%-35%, 35%-40%, 40%-45%, 45%-50%, 60%-70%, 70%-80%, 80%-90%, or 90%-95%. Alternatively, the isolation / purity may be expressed in terms of cell doublings, where the cells have undergone, for example, 10-20, 20-30, 30-40, 40-50 or more cell doublings.

[0020] The cells may be derived from one donor for expansion and returned to the same donor (autologous), or the cells may be derived from one donor for expansion and administered to a different subject (allogeneic), or the cells may be derived from different donors.

[0021] The cells may be amplified (grown) by any desired number of cell doublings. Ranges include 2-fold to 1000-fold or more. The limits depend on the ability to provide sufficient nutrients and remove harmful waste products. In some embodiments, cell doublings are within the range of about 2-fold to about 10-fold, about 10-fold to about 50-fold, and about 50-fold to about 100-fold. Using the techniques described herein, cell doublings of up to 10 8 More than one cell can be produced from a single donor.

[0022] Cells may be amplified, harvested, and then reintroduced into the bioreactor for further amplification. For purposes of this application, "run" refers to one round of amplification (from introduction of the cells to harvest). Thus, cells may be harvested after one or more runs. "Passage" refers to a run. Cells may be amplified by different cell doublings in each run. In one run, for example, cells may be amplified 2x10 fold. However, with repeated runs, the total amplification may be much higher (as above).

[0023] The cells of the present invention may express pluripotency markers (e.g., oct4). The cells may express markers associated with extended replicative capacity (e.g., telomerase). Other characterizations of pluripotency may include the ability to differentiate into cell types of more than one germ layer (e.g., two or three of the embryonic germ layers: ectoderm, endoderm, and mesoderm). Such cells may or may not be immortalized or transformed in culture. The cells may be highly expanded without transformation and also maintain a normal karyotype. For example, in one embodiment, non-embryonic stem non-germ cells may have undergone at least 10-40 (e.g., 50, 60, or more) cell doublings in culture, where the cells are not transformed and have a normal karyotype. The cells may differentiate into at least one cell type of each of two of the embryonic lineages: endoderm, ectoderm, and mesoderm, and may include differentiation into all three. Furthermore, the cells may not be tumorigenic, e.g., may not produce teratomas. If the cells are transformed or tumorigenic and it is desired to use the cells for injection, such cells may be disabled so that they cannot form tumors in vivo, such as by treatments that prevent the cells from proliferating into tumors. Such treatments are well known in the art.

[0024] Cells include, but are not limited to, the numbered embodiments below.

[0025] 1. Isolated and expanded non-embryonic, stem, non-germ cells, which have undergone at least 10-40 cell doublings in culture, and which express OCT4, are non-transformed, and have a normal karyotype.

[0026] 2. A non-embryonic, stem, non-germline cell of claim 1, further expressing one or more of telomerase, rex-1, rox-1 or sox-2.

[0027] 3. A non-embryonic, stem, non-germline cell of claim 1, capable of differentiating into at least one cell type of at least two of the endoderm, ectoderm and mesoderm embryonic lineages.

[0028] 4. A non-embryonic, stem, non-germline cell according to claim 3, further expressing one or more of telomerase, rex-1, rox-1 or sox-2.

[0029] 5. A non-embryonic, stem, non-germline cell of 3 above that can differentiate into at least one cell type of each of the endoderm, ectoderm and mesoderm embryonic lineages.

[0030] 6. A non-embryonic, stem, non-germline cell according to claim 5, further expressing one or more of telomerase, rex-1, rox-1 or sox-2.

[0031] 7. Isolated and expanded non-embryonic, stem, non-reproductive cells obtained by culture of non-embryonic, non-reproductive tissue, said cells having undergone at least 40 cell doublings in culture, said cells being non-transformed and having a normal karyotype.

[0032] 8. A non-embryonic, stem, non-germline cell of 7 above, which expresses one or more of oct4, telomerase, rex-1, rox-1 or sox-2.

[0033] 9. A non-embryonic, stem, non-germline cell of 7 above, capable of differentiating into at least one cell type of at least two of the embryonic lineages endoderm, ectoderm and mesoderm.

[0034] 10. A non-embryonic, stem, non-germline cell of claim 9, which expresses one or more of oct4, telomerase, rex-1, rox-1 or sox-2.

[0035] 11. A non-embryonic, stem, non-germline cell of claim 9, which is capable of differentiating into at least one cell type of each of the endoderm, ectoderm and mesoderm embryonic lineages.

[0036] 12. A non-embryonic, stem, non-germline cell of claim 11 which expresses one or more of oct4, telomerase, rex-1, rox-1 or sox-2.

[0037] 13. An isolated and expanded non-embryonic stem non-germline cell, said cell having undergone at least 10-40 cell doublings in culture, said cell expressing telomerase, being non-transformed and having a normal karyotype.

[0038] 14. A non-embryonic, stem, non-germline cell of claim 13, further comprising one or more of oct4, rex-1, rox-1 or sox-2 expressing said cell.

[0039] 15. A non-embryonic, stem, non-germline cell of claim 13, which is capable of differentiating into at least one cell type of at least two of the endoderm, ectoderm and mesoderm embryonic lineages.

[0040] 16. A non-embryonic, stem, non-germline cell of claim 15, further comprising one or more of oct4, rex-1, rox-1 or sox-2 expressing said cell.

[0041] 17. A non-embryonic, stem, non-germline cell of claim 15, which is capable of differentiating into at least one cell type of each of the endoderm, ectoderm and mesoderm embryonic lineages.

[0042] 18. A non-embryonic, stem, non-germline cell of claim 17, further comprising one or more of oct4, rex-1, rox-1 or sox-2.

[0043] 19. An isolated and expanded non-embryonic, stem, non-germline cell capable of differentiating into at least one cell type of at least two of the endoderm, ectoderm and mesoderm embryonic lineages, said cell having undergone at least 10-40 cell doublings in culture.

[0044] 20. A non-embryonic, stem, non-germline cell of claim 19 which expresses one or more of oct4, telomerase, rex-1, rox-1 or sox-2.

[0045] 21. A non-embryonic, stem, non-germline cell of claim 19, which is capable of differentiating into at least one cell type of each of the endoderm, ectoderm and mesoderm embryonic lineages.

[0046] 22. A non-embryonic, stem, non-germline cell of claim 21 which expresses one or more of oct4, telomerase, rex-1, rox-1 or sox-2.

[0047] The cells can be prepared from any desired tissue source, including, but not limited to, bone marrow, umbilical cord blood, umbilical cord matrix, peripheral blood, placenta, placental blood, muscle, brain, kidney and other solid organs. The cells can also be derived from excretory fluids (e.g., urine and menstrual blood).

[0048] In one embodiment, the cells are derived from human tissue.

[0049] In the construction of the hollow fiber bioreactor, there are several design considerations and several parameters that can be altered with the objectives related to the expansion of the cells. First, the number of fibers in the bioreactor can be altered. Multiple fibers or bundles of fibers are commonly used to provide the desired surface area and high density of cells. The actual range for the number of fibers also varies depending on the length of the fiber. Thus, the length is also variable. In general, the length of the fiber is limited only by the ability to efficiently contact the nutrient medium with the cells, remove waste or desired cell products, and effectively release the cells from the fiber matrix. Thus, the range of the fiber length can be varied. A further design consideration is the thickness of the fiber wall. The thickness of the wall is variable and is limited only by the parameters of efficiently supplying nutrients to the cells and efficiently removing waste or useful products from the cells. Another design consideration is the pore size of the fiber wall. The pore size of the fiber wall is generally designed to allow for the transfer of nutrients to the cells, the transport of waste products, the provision of desired products (e.g., growth factors) to the cells, the removal of desired products from the cells, etc. For example, pore size can be designed to prevent certain factors that may be present (e.g., in serum) from reaching the cells. A further design consideration is the internal dimensions of the hollow fibers (e.g., diameter of circular fibers). Selection considerations include adequate access of the culture medium to the cells, adequate access to provide adequate nutrients, adequate access to remove waste products, and adequate access to achieve a desired cell density. A further design consideration is the composition of the fiber wall. The composition can include a wide variety of biocompatible materials that provide a substrate to which cells can attach. In some embodiments, attachment can be improved by coating the wall material with an attachment-promoting substrate (e.g., extracellular matrix proteins).

[0050] Moreover, in a bioreactor, more than one type of fiber can be found, with respect to the various parameters mentioned above. Said fibers are useful, for example, when it is desired to co-culture different cell types. The optimal fiber design may differ for each cell.

[0051] The plurality of hollow fibers are typically housed in a shell that is desirably connected to inlets and outlets for perfusing media into and / or near the fibers. In one embodiment, the fibers are found as part of a growth chamber through which cell media is perfused (circulated) so that media flows into and / or near the fibers. In one embodiment, the fibers are housed in a cartridge that is connected to a pump for infusion of cell culture media and supplements.

[0052] Materials from which the fibers can be manufactured include a wide variety of biocompatible semi-permeable materials that allow for diffusion of nutrient medium through the fiber wall to supply the cells while at the same time allowing cell growth in three dimensions.

[0053] The cells according to the invention may be co-cultured with other cell types, either co-plated with the cells or attached separately or otherwise cultured in the expansion chamber. In one embodiment, the other cells may be attached to the inner surface (or outer surface) of the fiber before introducing the cells of the invention. Thus, the cells of the invention may be deposited on a monolayer of the desired cell type.

[0054] The hollow fibers may be pre-coated with one or more extracellular matrix proteins (e.g., Matrigel, fibronectin, or collagen) to enhance cell attachment. Extracellular matrix proteins may be attached to the inner and / or outer surfaces of the fibers. In general, extracellular matrix proteins may be attached to the surface by any of the methods described in U.S. Pat. Nos. 5,872,094 and 6,471,689, both of which are incorporated herein by reference for the teachings of these methods.

[0055] Flow rates are also variable depending on the cells to be amplified and the stage of the process. For example, after cell attachment is achieved, after cell seeding, the flow rate can be increased to a steady state level. The rate is increased after the cells attach and then increased again to facilitate collection of the cells from within the chamber.

[0056] Custom designed hollow fiber capillary culture systems can be manufactured on a contract basis by many different suppliers using readily available materials for mammalian cell culture. Some types of hollow fiber systems for cell culture are commercially available from companies such as FiberCell Systems, Inc. (Frederick, Md). The hollow fiber systems manufactured by FiberCell Systems are composed of fibers with a diameter of approximately 200 microns. The fibers are enclosed within a cartridge designed to allow cell culture medium flushed from the end of the cartridge to flow through the interior of the fibers. The cells are attached to a porous support and the culture can be maintained in continuous production for many months.

[0057] Analysis of the expanding / expanded cells may include expression of markers (e.g., those described herein). Additionally, loss of expression of hematopoietic markers (e.g., CD34 and CD45) may be analyzed. Sample supernatants and monolayers may be monitored periodically for (a) cell morphology, (b) ploidy, and (c) in situ hybridization for cell markers.

[0058] As noted above, the cells to be expanded in the bioreactor may first be isolated and cultured using other culture conditions, for example, the exemplary cells (designated "MAPC") may first be isolated and cultured as described herein below. In an embodiment of the present invention, for example, the following items are provided: (Item 1) 1. A method for ex vivo cell expansion, comprising: a) seeding the cells onto a hollow fiber substrate such that the cells adhere to the substrate; b) amplifying the attached cells on the substrate; and c) removing the amplified cells from the substrate. wherein the cell is a non-embryonic stem non-germ cell, and the cell expresses telomerase, is not transformed and has a normal karyotype. (Item 2) 2. The method according to item 1, further comprising: d) reseeding the removed cells onto the same or a different substrate; and e) repeating steps b) to d) until a desired number of amplified cells is reached. (Item 3) The method of item 2, further comprising administering the removed cells to a subject. (Item 4) 2. The method of claim 1, wherein the hollow fiber substrate is within a closed continuous perfusion bioreactor. (Item 5) 4. The method according to item 3, wherein the cells are amplified about 10 to 100 fold. (Item 6) 6. The method according to any one of claims 1 to 5, wherein the hollow fibre is coated. (Item 7) 7. The method of claim 6, wherein the coating is fibronectin. (Item 8) 8. The method of claim 7, wherein the wall material in the fiber is PA / PAES / PVP. (Item 9) The method according to any one of items 1 to 8, wherein the cells in step (a) comprise a substantially homogenous population. The method according to any one of items 1 to 8, wherein step (a) comprises seeding cells derived from a tissue, and the tissue is selected from bone marrow, umbilical cord blood, umbilical cord matrix, peripheral blood, placenta, placental blood, muscle, brain, kidney, or other solid organ. (Item 11) 2. The method of item 1, wherein the non-embryonic, stem, non-germ cells further express one or more of oct4, rex-1, rox-1 or sox-2. (Item 12) The method of items 1 and 11, wherein the non-embryonic stem non-germ cells can differentiate into at least one cell type of at least two embryonic lineages: endoderm, ectoderm and mesoderm. (Item 13) 13. The method of item 12, wherein the non-embryonic stem non-germ cells are capable of differentiating into at least one cell type of each of the endoderm, ectoderm and mesoderm embryonic lineages. [Brief description of the drawings]

[0059] [Figure 1] FIG. 1 provides a schematic diagram of the hollow fiber cell amplification system. [Diagram 2] FIG. 2 is a schematic diagram of a bioreactor that may be used in the present invention. [Diagram 3] Figure 3A shows a side view of an embodiment of a hollow fiber cell growth chamber in a cell growth chamber, and Figure 3B shows a cross-sectional side view of the hollow fiber cell growth chamber in the embodiment of Figure 3A. [Figure 4] Figure 4 - Block diagram of the fluid circuit of the Cell Amplification System (CES), showing the system and all bag connections. [Diagram 5] FIG. 5—Flow scheme for the Quantum Cell Expansion System from Caridian BCT (now owned by Terumo) used to expand MultiStem from bone marrow or cell banks. [Figure 6]Figure 6 - Whole bone marrow aspirate was seeded into the Quantum without bone marrow mononuclear cell (BMMNC) preselection and BMMNC from the same donot were seeded onto regular cell culture plastic. This was done for 3 independent donors. Cells in T75 were passaged at least 3 times and cell counts were used to calculate population doublings (PD). Cells in the Quantum were harvested, counted, placed into a new bioreactor and harvested again after 6 days. The rate of expansion for MultiStem starting from bone marrow aspirate in the Quantum is not significantly different from expansion on cell culture plastic. [Figure 7] FIG. 7 - Starting from bone marrow aspirates, a MultiStem master cell bank can be generated within 17 days. [Figure 8] FIG. 8--A more detailed view of the device of FIG. [Figure 9] Figure 9 - Overview of an embodiment of continuous perfusion hollow fiber bioreactor amplification in a closed system. [Figure 10] FIG. 10 - Overview of the manufacturing process from isolating cells from qualified donors, to creating a master cell bank, and then administering the cells to the patient. [Figure 11] Figure 11 - Overview of cell banking efforts. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0060] Detailed Description of the Invention It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc. described herein and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the disclosed invention, which is defined solely by the claims.

[0061] Section headings are used herein for organizational purposes only and should not be construed as limiting the subject matter described in any way.

[0062] The methods and techniques of the present application are generally based on conventional methods, unless otherwise specified, well known in the art and described in various general and more specific references cited and described throughout this specification.See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2001), Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992), and Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1990).

[0063] definition As used herein, "a" or "an" means one or more than one; at least one. When the plural is used herein, it generally includes the singular form.

[0064] The term "bioreactor" refers to a cell culture system that supplies cells with nutrients, removes metabolic products, and provides a physicochemical environment conducive to cell growth in a closed, sterile system.

[0065] As used herein, the term "bioreactor" refers to any device in which biological and / or biochemical processes proceed under monitored and controlled environmental and operational conditions (e.g., pH, temperature, pressure, nutrient supply and waste product removal). In accordance with the present invention, a basic classification of bioreactors suitable for use in the present invention includes hollow fiber bioreactors.

[0066] "Cell bank" is the industry term for cells that have been grown and stored for future use. Cells may be stored in aliquots. The cells may be used directly out of storage or may be expanded after storage. This is convenient since there are cells "in stock" available for administration. The cells may already be stored in a pharma- ceutically acceptable excipient so that they may be administered directly, or may be mixed with a suitable excipient when removed from storage. The cells may be frozen or otherwise stored in a form that preserves viability. In one embodiment of the invention, a cell bank is created in which cells are selected for enhanced modulation of macrophage activation. After removal from storage and prior to administration to a subject, it may be preferable to re-assay the cells for potency, i.e., the level of modulation of macrophage activation. This may be done using any of the direct or indirect assays described herein or otherwise known in the art. Cells with the desired potency may then be administered to the subject for treatment. The bank may be made using cells from the individual to be treated (either from their prenatal tissues (e.g., placenta, umbilical cord blood or umbilical cord matrix) or expanded from the individual at any time after birth (autologous). Alternatively, the bank may contain cells for allogeneic use. A master cell bank is a cell reservoir that provides an aliquot of cells that can be further expanded to provide a dose for administration to a subject.

[0067] A "clinically relevant" number of cells refers to a number of cells sufficient to effect a clinical response (i.e., prevention, reduction, amelioration, etc. of an undesirable condition in a subject). Certain embodiments relate to a number of cells sufficient to generate a master cell bank.

[0068] "Co-administer" means the administration of two or more agents in conjunction with, in conjunction with, or in coordination with one another, including simultaneous or sequential administration.

[0069] "Comprising" means necessarily including the referent without other limitations, other qualifications, or exclusion of what may otherwise be included. For example, "a composition comprising x and y" includes any composition comprising x and y, whatever other components may be present in the composition. Similarly, "a method comprising the step x" includes any method in which x is performed, regardless of whether x is the only step or only one of the steps in the method, no matter how many other steps may be present and how simple or complex x may be in comparison. "Comprised of" and similar expressions using the word "comprise" stem are used herein as synonyms of "comprising" and have the same meaning.

[0070] "Comprosed of" is a synonym of "comprising" (see above).

[0071] "Conditioned cell culture medium" is a term well known in the art and refers to medium after cells have been grown. As used herein, this means that the cells have been grown for a period of time sufficient to secrete factors effective to achieve any of the results described herein.

[0072] Conditioned cell culture medium refers to the medium after cells are cultured to secrete factors into said medium. For the purpose of the present invention, cells can be propagated through a sufficient number of cell divisions to produce an effective amount of such factors so that said medium has this effect. Cells are removed from said medium by any method known in the art, including but not limited to centrifugation, filtration, immunodepletion (e.g., by tagged antibody and magnetic column) and FACS sorting.

[0073] "EC cells" were discovered from the analysis of a type of cancer called teratocarcinoma. In 1964, researchers realized that a single cell in a teratocarcinoma could be isolated and remained undifferentiated in culture. This type of stem cell became known as an embryonic carcinoma cell (EC cell).

[0074] "Effective amount" generally refers to an amount that provides a desired local or systemic effect. For example, an effective amount is an amount that is sufficient to achieve a beneficial or desired clinical result. The effective amount may be provided all at once in one administration, or in divided amounts that provide an effective amount in several administrations. The exact determination of what is considered an effective amount may be based on factors unique to each subject, including size, age, injury and / or disease or injury being treated, and the time since the injury occurred or the disease began. Those skilled in the art can determine the effective amount for a given subject based on these considerations that are routine in the art. As used herein, "effective dose" means the same as "effective amount."

[0075] "Effective route" generally refers to a route that provides for delivery of a drug to a desired compartment, system, or location. For example, an effective route is one through which a drug can be administered that provides a sufficient amount of the drug at the desired site of action to achieve a beneficial or desired clinical result.

[0076] "Embryonic stem cells (ESCs)" are well known in the art and have been prepared from many different mammalian species. Embryonic stem cells are stem cells derived from the inner cell mass of an early embryo known as a blastocyst. Embryonic stem cells can differentiate into all derivatives of the three primary germ layers (ectoderm, endoderm and mesoderm). These include each of the more than 220 cell types in the adult. ES cells can become any tissue in the body except the placenta. Only morula cells are totipotent and can become all tissues and the placenta. Some cells similar to ESCs can be produced by nuclear transfer of the nucleus of a somatic cell into an enucleated fertilized egg.

[0077] By "expand" is meant achieving a clinically relevant number of cell divisions of output cells. "Clinically relevant" means that sufficient cell doublings of these cells are achieved within and / or on the fibers to provide a clinically relevant number of output cells. Hollow fiber bioreactor technology has been used for purposes other than actual cell expansion to produce a clinically relevant number of output cells. For example, such bioreactors have been used to differentiate input populations of cells, enrich input populations of cells, process blood and other fluids by means of input populations of cells, and the like. In these embodiments, the cells that are attached to the fibers are not, in fact, output cells. The cells are attached to the fibers for another purpose, not for expansion. Nevertheless, within the time frame used to achieve these other purposes, some of the input cells may in fact be amplified. What distinguishes this from the present technology is that cell expansion is not achieved in clinically relevant numbers. Cell doublings are limited.

[0078] The term "hollow fiber" is intended to include hollow structures (of any shape) that contain pores of defined size, shape and density for use in delivering (dissolved) nutrients to cells contained within a bioreactor and for removing (dissolved) waste products from cells contained within a bioreactor. For purposes of the present invention, hollow fibers may be constructed of resorbable or non-resorbable materials. Fibers include, but are not limited to, tubular structures.

[0079] The use of the term "include" is not intended to be limiting.

[0080] "Increase" or "increasing" means to induce completely where none was present before, or to increase in extent.

[0081] "Induced pluripotent stem cells (IPSCs or IPS cells)" are somatic cells that have been reprogrammed, for example, by introducing exogenous genes that confer a less differentiated phenotype into the somatic cells. These cells can then be induced to differentiate into less differentiated progeny. IPS cells have been derived using a modified version of an approach that was first discovered in 2006 (Yamanaka, S. et al., Cell Stem Cell, 1:39-49 (2007)). For example, in one example, to create IPS cells, scientists started with skin cells and then modified them by standard laboratory techniques that use retroviruses to insert genes into the cell's DNA. In one example, the inserted genes were Oct4, Sox2, Lif4 and c-myc, known to act together as natural regulators that maintain cells in an embryonic stem cell-like state. These cells have been described in the literature. See, for example, Wernig et al., PNAS, 105:5856-5861 (2008); Jaenisch et al., Cell, 132:567-582 (2008); Hanna et al., Cell, 133:250-264 (2008); and Brambrink et al., Cell Stem Cell, 2:151-159 (2008). These references are incorporated by reference for their teaching of IPSCs and methods of producing them. It is also possible that such cells can be generated by specific culture conditions (exposure to specific drugs).

[0082] The "input cell population" refers to a cell type that is introduced into the bioreactor for amplification of that cell type, ultimately forming the output cell population. The input cell population may be introduced into the bioreactor in very low numbers. For example, in bone marrow, the desired input cell population may initially be found in as few as one cell per million. Alternatively, the input population may be substantially homogenous, e.g., derived from a cell bank and further amplified in the bioreactor.

[0083] The term "isolated" refers to a cell or cells that is free from association with one or more cells or one or more cellular components that are associated with the cell or cells in vivo. An "enriched population" refers to a relative increase in the number of desired cells compared to one or more other cell types in vivo or in primary culture.

[0084] However, as used herein, the term "isolated" does not indicate that only stem cells are present. Rather, the term "isolated" indicates that the cells are removed from their natural tissue environment and are present in a higher concentration compared to the normal tissue environment. Thus, an "isolated" cell population may further include cell types in addition to stem cells, and may include additional tissue components. This may also be expressed, for example, in terms of cell doublings. Cells may undergo 10, 20, 30, 40 or more doublings in vitro or ex vivo so as to be enriched compared to their original number in vivo or in their original tissue environment (e.g., bone marrow, peripheral blood, adipose tissue, etc.).

[0085] "MAPC" is an acronym for "multipotent adult progenitor cells." MAPCs refer to cells that are neither embryonic stem cells nor germ cells, but have some characteristics of these. MAPCs can be characterized in many alternative descriptions, each of which conferred novelty to the cells when they were discovered. Thus, MAPCs can be characterized by one or more of these descriptions. First, MAPCs are not transformed (tumorigenic), have normal karyotypes, and have extended replicative potential in culture. Second, upon differentiation, MAPCs can give rise to progeny cells of two or more germ layers, such as two or all three germ layers (i.e., endoderm, mesoderm, and ectoderm). Third, MAPCs are neither embryonic stem cells nor germ cells, but they can express markers of these primitive cell types, such as MAPCs can express one or more of Oct3 / 4 (i.e., Oct3A), rex-1, and rox-1. MAPCs may also express one or more of sox-2 and SSEA-4. Fourth, like stem cells, MAPCs can self-renew, i.e., have extended replicative potential without being transformed. This means that these cells express telomerase (i.e., have telomerase activity). Thus, the cell type designated "MAPC" may be characterized by other fundamental properties that describe the cells by some of their novel properties.

[0086] The term "adult" in MAPC is non-limiting. The adult refers to non-embryonic somatic cells. MAPC are karyotypically normal and do not form teratomas in vivo. This acronym was first used in U.S. Pat. No. 7,015,037 to describe pluripotent cells isolated from bone marrow. However, cells with pluripotent markers and / or differentiation potential have been discovered subsequently and may be equivalent, for the purposes of the present invention, to the cells originally named "MAPC". An essential description of MAPC type cells is provided in the Summary of the Invention above.

[0087] MAPCs represent a more undifferentiated progenitor population than MSCs (Verfaillie, CM, Trends Cell Biol 12:502-8 (2002); Jahagirdar, BN et al., Exp Hematol, 29:543-56 (2001); Reyes, M. and CM Verfaillie, Ann NY Acad Sci, 938:231-233 (2001); Jiang, Y. et al., Exp Hematol, 30896-904 (2002); and Jiang, Y. et al., Nature, 418:41-9. (2002)).

[0088] The term "MultiStem®" is the trade name for the MAPC-based cell preparation of U.S. Patent No. 7,015,037, i.e., non-embryonic, stem, non-germ cells as described above. MultiStem® is prepared according to the cell culture method disclosed in this patent application, particularly with lower oxygen and higher serum concentrations. MultiStem® is highly proliferative, karyotypically normal, and does not form teratomas in vivo. MultiStem® can differentiate into cell lineages of two or more germ layers and express one or more of telomerase, oct3 / 4, rex-1, rox-1, sox-2, and SSEA4.

[0089] The term "nutrient solution" is intended to include the solution that enters the bioreactor and contains nutritional materials essential for the culture of mammalian or vertebrate cells. The nutrient solution may contain additives that affect specific changes in the phenotype of the cells in culture or that contribute to changes in the matrix structure of the newly formed bone being formed (e.g., mineralization).

[0090] Nutrients may be delivered to the cells in the bioreactor to affect the proliferation and differentiation of cells contained in the bioreactor. The nutrient solution is selected to supply the cells with sufficient nutrients to maintain viability, proliferation and / or differentiation in the bioreactor. Those skilled in the art can select a suitable nutrient solution for the present invention. For example, a culture medium such as Dulbecco's Modified Eagle Medium may be used and may be supplemented with other suitable nutrients. Other suitable nutrients include fetal bovine serum, L-ascorbic acid, -2-phosphate, antibiotics, cell modulators such as dexamethasone, β-glycerol phosphate, glucose, glutamine, amino acid supplements, inhibitors (or activators) of apoptosis such as glutathione-ethyl ester, antioxidants, caspase inhibitors, and cations and anions such as magnesium, manganese, calcium, phosphate, chloride, sodium, potassium, zinc and sulfate ions, and nitrate and nitrite ions. The remaining concentrations of components in the nutrient solution should be sufficient to promote growth and maintain viability of the cells in the bioreactor.

[0091] The "output cell population" refers to the cells one wishes to harvest from the bioreactor after they have been expanded in the bioreactor. Harvested cells are defined as those that are removed from the bioreactor and then used for clinical or other purposes, e.g., research, clinical trials, etc.

[0092] "Primordial embryonic germ cells" (PG or EG cells) can be cultured and stimulated to give rise to many less differentiated cell types.

[0093] "Progenitor cells" are cells generated during differentiation of stem cells that have some, but not all, of the characteristics of their terminally differentiated progeny. Definition of progenitor cells, e.g., "cardiac progenitor cells," are committed to a lineage, but not to a specific or terminally differentiated cell type. The term "progenitor" when used in the acronym "MAPC" does not limit these cells to a specific lineage. Progenitor cells can form progeny cells that are more highly differentiated than the progenitor cells.

[0094] Selection can be performed from cells in a tissue, for example, where cells are isolated from the desired tissue, expanded in culture, selected for the desired property, and the selected cells are further expanded.

[0095] "Self-renewal" refers to the ability to generate replicate daughter stem cells that have the same differentiation potential as the cell that generated them. A similar term used in this context is "proliferation."

[0096] "Serum-free medium" refers to medium in which serum is absent or, if present, serum is at a level where the serum components do not affect cell growth or viability (i.e., are not actually required, e.g., are in residual or trace amounts).

[0097] "Stem cell" refers to a cell that can undergo self-renewal (i.e., progeny with the same differentiation potential) and generate progeny cells with more committed differentiation potential. Within the context of the present invention, stem cells also encompass more differentiated cells that have been dedifferentiated (e.g., by nuclear transfer, fusion with more primitive stem cells, introduction of specific transcription factors, or culture under specific conditions). See, for example, Wilmut et al., Nature, 385:810-813 (1997); Ying et al., Nature, 416:545-548 (2002); Guan et al., Nature, 440:1199-1203 (2006); Takahashi et al., Cell, 126:663-676 (2006); Okita et al., Nature, 448:313-317 (2007) and Takahashi et al., Cell, 131:861-872 (2007).

[0098] Differentiation can also be caused by administration of a specific compound that causes differentiation, or exposure to a physical environment in vitro or in vivo.Stem cells can be derived from abnormal tissues, such as teratocarcinomas, and from some other sources, such as embryoid bodies (these can be considered as embryonic stem cells in that they are derived from embryonic tissues, but are not directly derived from the inner cell mass).Stem cells can also be produced by introducing genes related to stem cell function into non-stem cells, such as induced pluripotent stem cells.

[0099] "Subject" means a vertebrate, e.g., a mammal, e.g., a human. Mammals include, but are not limited to, humans, dogs, cats, horses, cows and pigs.

[0100] The term "effluent" is intended to include the solution exiting the bioreactor and containing waste by-products of cellular metabolism. The concentration of waste by-products (e.g., ammonia, lactic acid, etc.) and the remaining levels of nutrients (e.g., glucose) in the effluent can be used to assess the metabolic activity level of the cells being cultured in the bioreactor.

[0101] Bioreactor Bioreactors, particularly those used in tissue regeneration processes, are well known (see, e.g., U.S. Patent Nos. 6,306,169; 6,197,575; 6,080,581; 5,677,355; 5,433,909; and 5,898,040, which are incorporated by reference).

[0102] Bioreactor is a generalized term that essentially encompasses any type of vessel in which cells can be cultured and that provides some degree of protection for the cells' environment. Bioreactors can be stationary vessels (e.g., flasks or culture bags) in which variables (e.g., growth medium composition, oxygen concentration, pH level, and osmolarity) are not fully controlled or monitored. On the other hand, fully automated, electromechanical, state-of-the-art bioreactors exist in which all the above variables are monitored and controllable. Many combinations between these examples are well known to those skilled in the art of cell biotechnology.

[0103] Three different traditional approaches to the culture of isolated hematopoietic stem or progenitor cells have been described in the literature: static culture, agitated culture and immobilized culture. Static culture is performed in very simple culture systems, e.g., well plates, tissue culture flasks or gas-permeable culture bags. The latter is in fact the most frequently used technique for stem cell expansion, since the former two systems do not allow cell culture on a clinical scale (Purdy et al., J. Hematother, 4:515-525 (1995); McNiece et al., Hematol Cell Ther, 4:82-86 (1999); and McNiece et al., Exp Hematol, 28:1181-1186 (2000a)). All these systems have the advantage of being easy-to-handle, disposable instruments, which allows for easy cell collection. However, in all these systems, process control regulation is provided via control of the incubator environment, and no continuous supply is provided. For this reason, variations in culture conditions (e.g., oxygen tension, pH, concentrations of substrates, metabolites and cytokines) during cultivation are important factors in all three static culture methods.

[0104] Stirred bioreactors are commonly used for animal cell culture and provide a homogenous environment, representative sample extraction, better access for process control, and improved oxygen transfer. Several stirred technologies (spinner flasks and stirred vessel bioreactors) have been successfully implemented for the culture of hematopoietic cells (Zandstra et al., Biotechnol, 12:909-914 (1994)).

[0105] Immobilization of stem and progenitor cells is an attempt to achieve high local cell density and mimic the three-dimensional structure of tissues (e.g., bone marrow) without the use of stromal feeder layers. In immobilized biocatalytic reactors, the cells are immobilized in or on carriers, and may be immobilized by bonding with each other to form larger particles, or may be confined within a membrane barrier. Most reactors can be run in batch, fed-batch, or continuous modes. Immobilized bioreactors are well known in the art and include, for example, conventional reactors, such as continuous stirred tank reactors (CSTRs) and packed bed reactors (PBRs), as described in standard textbooks, for example, Ullmann's Encyclopedia Of Industrial Chemistry: Fifth edition, edited by T. Campbell, R. Pfefferkom and JF Rounsaville, VCH Publishers 1985, Vol A4, pp 141-170; Ullmann's Encyclopedia Of Industrial Chemistry: Fifth ed., edited by B. Elvers, S. Hawkins and G. Schulz, VCH Publishers 1992, Vol B4, pp 381-433; J.B. Butt, "Reaction Kinetics And Reactor Design", Prentice-Hall, Inc., 1980, pp 185-241.

[0106] Thus, bioreactors can be classified based on general categories including static bioreactors, stirred flask bioreactors, rotating wall vessel bioreactors, hollow fiber bioreactors and direct perfusion bioreactors, in which cells can be in suspension or immobilized by seeding on a porous three-dimensional scaffold (hydrogel).

[0107] Hollow fiber bioreactors can be used to improve mass transfer during cultivation. Thus, in the context of the present invention, the bioreactor is a hollow fiber bioreactor. A hollow fiber bioreactor may have the stem and / or progenitor cells embedded in the lumen of the fiber, with medium perfusing the extraluminal space, or alternatively, a hollow fiber bioreactor may provide perfusion of gas and medium through the hollow fiber, with the cells growing in the extraluminal space. Such hollow fiber bioreactors suitable for the present invention are disclosed herein and some are commercially available, such as, for example, the Caridian (Terumo) BCT Quantum Cell Expansion System.

[0108] A bioreactor is defined as any device that provides the physiological requirements of cells (e.g., pH, temperature, pressure, nutrients, feed and waste removal) for standard production of cells and cell products. Bioreactors can improve mass transfer in engineered bioreactors for cell growth. There is continuous nutritional uptake and waste removal of cells. For autologous administration of cells, the bioreactor should be relatively compact, disposable and economical. Generally, a large chamber / volume ratio is required. Finally, growth factors or serum components may be required to maintain the cells in a specific differentiation state. For this reason, a medium-containing bioreactor is desirable. These requirements are met by the hollow fiber bioreactor-based cell expansion system described in Antwiler et al.

[0109] In the apparatus described in Antwiler et al., the system provides a chamber growth volume of approximately 120 ml, although larger chamber volumes can be accommodated. 2A surface area of ​​100 μm is provided. Thus, both adherent and suspension cells can be grown in this device, including co-culture. Other physical characteristics are: length 295 mm; inner diameter 215 μm; IC volume 104 ml; EC volume 330 ml; number of fibers 9000. Fibronectin may be used as a coating for adherent cells. The device can maintain all experimental conditions required to grow cells of interest, such as gas concentration, pH, medium, temperature, nutrients, waste management and necessary additives. To prevent contamination, the system is designed to have closed sterile fluid compartments. Media reagent and solution bags remain attached to the system so that the supply schedule, waste removal and general cell culture environment can be replaced, controlled and optimized as desired. The unit can be used on a benchtop. Cells can be grown inside (intracapillary), outside (extracapillary) or on both sides of the fibers simultaneously. This hollow fiber bioreactor design allows for direct connections using tubing that can be plumbed through appropriate aerial pumps, pinch valves, etc. to obtain a closed system. Gas control is managed using a hollow fiber oxygenator. The system also accommodates the ability to add and harvest cells, change media, add reagents, etc. For this reason, bags are used for all fluids and all bag connections use sterile connection techniques. A schematic diagram can be found in Figure 4.

[0110] In an exemplary embodiment (Example 1) of this application, the continuous flow bioreactor has an internal fluid volume of 184 ml and an external fluid volume of 303 ml, with a total surface area (within the capillaries) of approximately 2.1 m 2 (3255in 2 ), with a wall thickness of 50 μm, an inner diameter of 215 μm and a length of 295 mm, 4 The hollow fibers have a pore size with a 16 kDa cutoff for component passage.

[0111] The hollow fibers should be suitable for the delivery of nutrients and removal of waste products in the bioreactor. The hollow fibers may be of any shape, for example, circular and tubular, or in the shape of concentric rings. The hollow fibers may be made of resorbable or non-resorbable membranes. For example, suitable components of the hollow fibers include polydioxanone, polylactide, polyglactin, polyglycolic acid, polylactic acid, polyglycolic acid / trimethylene carbonate, cellulose, methylcellulose, cellulose polymers, cellulose esters, regenerated cellulose, pluronics, collagen, elastin, and mixtures thereof. A wide variety of suitable materials are well known in the art and have been proposed in numerous publications.Examples of these materials are U.S. Pat. Nos. 4,220,725; 4,184,922; 4,200,689; 3,821,087; 3,883,393; 4,184,922; 4,200,689; 3,997,396; 4,220,725; 4,999,298; 4,804,628; 5,126,238 No. 5,656,421; U.S. Patent No. 5,162,225; U.S. Patent No. 5,622,857; U.S. Patent No. 5,627,070; U.S. Patent No. 6,001,585; U.S. Patent No. 6,911,201; U.S. Patent No. 6,933,144; U.S. Patent No. 7,534,609; and U.S. Patent Application Publication No. 2007 / 0298497; U.S. Patent Application Publication No. 2008 / 0220523; U.S. Patent Application Publication No. 2001 / 0044413 No. 2009 / 0196901; U.S. Patent Application Publication No. 2010 / 0233130; U.S. Patent Application Publication No. 2009 / 0191631; U.S. Patent Application Publication No. 2005 / 0032218; U.S. Patent Application Publication No. 2005 / 0003530; U.S. Patent Application Publication No. 2003 / 0224510; U.S. Patent Application Publication No. 2006 / 0205071; U.S. Patent Application Publication No. 2010 / 0267134; U.S. Patent Application Publication No. 2008 / 02 No. 06733; U.S. Patent Application Publication No. 2010 / 0209403; U.S. Patent Application Publication No. 2008 / 0213894; U.S. Patent Application Publication No. 2008 / 0220522; U.S. Patent Application Publication No. 2008 / 0227190; U.S. Patent Application Publication No. 2008 / 0248572; U.S. Patent Application Publication No. 2008 / 0254533; U.S. Patent Application Publication No. 2010 / 0144037; and U.S. Patent Application Publication No. 2010 / 0042260, all of which are incorporated by reference for the teachings of these materials.Criteria for the wall material include, but are not limited to, the following: non-toxic to cells; porous for removal of waste products and receipt of nutrients, e.g., if collection of components secreted by the cells is desired, the porosity is adjusted for that parameter; relatively insensitive to temperature changes, i.e., thermally stable; and capable of retaining shape integrity.

[0112] Although such materials are not permeable to cells, it is also known that various desired materials are permeable. Thus, the hollow fibers contain pores that allow nutrients and waste products to pass in and out of the fibers. The pores of the hollow fibers are of sufficient diameter to allow molecules to diffuse from one side of the hollow fiber to the other side of the hollow fiber. Preferably, the molecules that can pass through the pores of the hollow fibers are about 0.002 to about 50 kDa, more preferably about 5 to about 25 kDa, or most preferably about 2 to about 16 kDa. Thus, the pore size of the fiber wall can be altered depending on the components desired to pass through the wall. For example, the pore size may only allow small molecules to pass or may be larger to allow the passage of large proteinaceous molecules, including growth factors, including but not limited to epidermal growth factor and platelet derived growth factor. One skilled in the art would understand how to alter the pore size depending on the components desired to pass through the fiber wall to reach the cells or to carry materials from the cells. For example, it may be desirable to collect components produced by the cells for further use. The cells may express and secrete, for example, cytokines, growth factors, immunomodulators, and other components that may be further useful. Materials that may be carried away from the cells also include waste products that one wishes to remove from the cells. Thus, this technique may be used to produce medium conditioned by cells that contains useful components.

[0113] Numerous bioreactor configurations exist for culturing anchorage-dependent cells, such as those of the present invention. However, the present invention is not dependent on any particular configuration. One example is provided in U.S. Patent Application Publication No. 2007 / 0298497, which discloses a configuration that has been used to grow mesenchymal stem cells.

[0114] One example (not meant to be limiting) in US 2007 / 0298497 is the hollow fiber bioreactor shown in Figure 2. A cell amplification module or bioreactor 10 that can be used in the present invention is made from a bundle of hollow fiber membranes 12 enclosed within a housing 14. The bundle of hollow fibers is collectively referred to as a membrane. The housing or module 14 is cylindrical in shape and can be made from any type of biocompatible polymeric material.

[0115] Each end of the module 14 is closed with an end cap or header 16, 18. The end caps 16, 18 can be made of any suitable material, for example polycarbonate, so long as the material is biocompatible with the cells to be grown in the bioreactor.

[0116] There may be at least four ports into and out of the module. Two ports are fluidly connected to the extracapillary space (EC space), one port 34 for introducing fresh extracapillary medium into the space surrounding the hollow fibers and one port 44 for introducing spent extracapillary medium out of the module. Two ports are also fluidly connected to the intracapillary space (IC space), one port 26 for introducing fresh intracapillary medium into the lumen of the hollow fibers as well as for introducing the cells to be amplified. One port 42 for introducing spent intracapillary medium and removing amplified cells from the bioreactor.

[0117] Cells to be expanded in the bioreactor can be flowed into the IC or EC space. The bioreactor can be loaded with cells using a syringe or the cells can be dispensed into the IC or EC space directly from a cell separator. The cells can be introduced into the expansion module or bioreactor from a cell input bag or flask (shown as element 5) that can be sterilely docked to the bioreactor.

[0118] In one embodiment, the hollow fiber wall materials that may be used include, but are not limited to, two types: 0.5% thermoplastic polyurethane sold under the trade name Desmopan® (available from Bayer MaterialScience AG, DE), and Polyflux®, which is the trade name for dialysis devices having membranes of Polyamix® (a blend of polyamide, polyarylethersulfone and polyvinylpyrrolidone) (available from Gambro Dialysatoren, GmBH, Hechingen, Del.) (Hoenich et al. (2000) ASAIO J., 46:70-75, incorporated by reference).

[0119] US Patent Application Publication No. 2008 / 0220523 provides a cell expansion system and methods for its use, which in certain embodiments are suitable for expanding the cells described herein. The cell expansion system generally includes a hollow fiber cell expansion chamber and first and second circulation loops (intracapillary and extracapillary loops) associated with the inside of the hollow fiber and the outside of the hollow fiber, respectively. A removable flow circuit and a cell expansion method are also provided. The cell expansion chamber is described below and is also shown in FIG. 3.

[0120] Cell Growth Chambers (U.S. Patent Application Publication No. 2008 / 0220523) The cell growth chamber of the cell growth system generally includes a hollow fiber membrane comprised of a plurality of semi-permeable hollow fibers that divides into a first fluid circulation path and a second fluid circulation path.

[0121] An exemplary cell growth chamber is shown in Figure 3, which shows a cross-sectional side view of a hollow fiber cell growth chamber 200. Cell growth chamber 200 is bounded by cell growth chamber housing 202. Cell growth chamber housing 202 further includes four openings, or ports: inlet 204, outlet 206, inlet 208 and outlet 210.

[0122] Fluid in the first circulation path enters the cell growth chamber 200 through inlet 204, passes into and through the capillary interior of the hollow fibers (referred to in various embodiments as the intra-capillary ("IC") side of the hollow fiber membrane or the "IC space"), and exits the cell growth chamber 200 through outlet 206. The terms "hollow fiber," "hollow fiber capillary," and "capillary" are used interchangeably. The hollow fibers are collectively referred to as the "membrane." Fluid in the second circulation path flows into the cell growth chamber through inlet 208, contacts the outside of the hollow fibers (referred to as the "EC side" or "EC space" of the membrane), and exits the cell growth chamber 200 via outlet 210. Cells can be contained within the first or second circulation path, and may be present on either the IC or EC side of the membrane.

[0123] The cell growth chamber housing 202 is shown as cylindrical in shape, but may have any other shape known in the art. The cell growth chamber housing 202 may be manufactured from any type of biocompatible polymeric material. Various other cell growth chamber housings may vary in shape and size.

[0124] Those skilled in the art will recognize that the term "cell growth chamber" does not mean that all cells grown or expanded in a cell expansion system are grown in the cell growth chamber. Adherent cells may adhere to a membrane disposed in the growth chamber or may grow within an associated tube. Non-adherent cells (also referred to as "suspension cells") may also be grown. Cells may be grown in other regions within the first or second fluid circulation paths.

[0125] For example, the ends of hollow fibers 212 may be potted into the sides of the cell growth chamber with a connecting material (also referred to herein as "potting" or "potting material"). The potting may be any suitable material for joining hollow fibers 212 together, provided that the flow of media and cells into the hollow fibers is not impeded and that liquids flowing through the IC inlet into the cell growth chamber flow only into the hollow fibers. Exemplary potting materials include, but are not limited to, polyurethane or other suitable bonding or adhesive compounds. In various embodiments, the hollow fibers and potting may be cut at both ends to pass perpendicular to the central axis of the hollow fibers to allow fluids to flow in and out of the IC sides. End caps 214 and 216 are disposed at the ends of the cell growth chamber.

[0126] Fluid entering the cell growth chamber 200 through the inlet 208 comes into contact with the outside of the hollow fibers. This portion of the hollow fiber cell growth chamber is referred to as the "extracapillary (EC) space." Small molecules (e.g., water, oxygen, lactate, etc.) can diffuse through the hollow fibers from the interior of the hollow fibers to the EC space or from the EC space to the IC space. Larger molecular weight molecules are typically too large to pass through the hollow fibers and remain in the IC space of the hollow fibers. The medium can be changed as needed. Medium may be circulated through an oxygenator to exchange gases as needed.

[0127] In various embodiments, cells may be placed into the hollow fibers by any of a variety of methods, including by syringe. The cells may be introduced into the cell growth chamber from a fluid container, e.g., a bag, which may be fluidly connected to the cell growth chamber.

[0128] The hollow fibers are configured to allow for cell growth in the intracapillary space of the fibers (i.e., within the hollow fiber lumen). The hollow fibers are large enough to allow for attachment of cells in the lumen without substantially impeding the flow of medium through the hollow fiber lumen. In various embodiments, the inner diameter of the hollow fibers can be 10,000 microns or more, 9,000 microns or more, 8,000 microns or more, 7,000 microns or more, 6,000 microns or more, 5,000 microns or more, 4,000 microns or more, 3,000 microns or more, 2,000 microns or more, 1,000 microns or more, 900 microns or more, 800 microns or more, 700 microns or more, 650 microns or more, 600 microns or more, 550 microns or more, 500 microns or more, 450 microns or more, 400 microns or more, 350 microns or more, 300 microns or more, 250 microns or more, 200 microns or more, 150 microns or more, or 100 microns or more. Similarly, the outer diameter of the hollow fibers can be 10,000 microns or less, 9,000 microns or less, 8,000 microns or less, 7,000 microns or less, 6,000 microns or less, 5,000 microns or less, 4,000 microns or less, 3,000 microns or less, 2,000 microns or less, 1,000 microns or less, 900 microns or less, 800 microns or less, 700 microns or less, 650 microns or less, 700 microns or less, 650 microns or less, 600 microns or less, 550 microns or less, 500 microns or less, 450 microns or less, 400 microns or less, 350 microns or less, 300 microns or less, 250 microns or less, 200 microns or less, 150 microns or less, or 100 microns or less. The thickness of the walls of the hollow fibers is sufficient to allow diffusion of small molecules.

[0129] Any number of hollow fibers may be used in a cell growth chamber, provided that the hollow fibers are fluidly connected to the inlets and outlets of the cell growth chamber. In various embodiments, the cell growth chamber may include 1000 or more, 2000 or more, 3000 or more, 4000 or more, 5000 or more, 6000 or more, 7000 or more, 8000 or more, 9000 or more, 10000 or more, 11000 or more, or 12000 or more hollow fibers. In other embodiments, the cell growth chamber may include 12000 or less, 11000 or less, 10000 or less, 9000 or less, 8000 or less, 7000 or less, 6000 or less, 5000 or less, 4000 or less, 3000 or less, or 2000 or less hollow fibers. In various other embodiments, the length of the hollow fibers can be 100 millimeters or more, 200 millimeters or more, 300 millimeters or more, 400 millimeters or more, 500 millimeters or more, 600 millimeters or more, 700 millimeters or more, 800 millimeters or more, or 900 millimeters or more. In one embodiment, the cell growth chamber comprises approximately 9000 hollow fibers having an average length of 295 mm, an average inner diameter of 215 microns, and an average outer diameter of 315 microns.

[0130] Hollow fibers can be made of any material that can be formed to a size sufficient to form a fiber capable of transporting liquid from the inlet of the cell growth chamber to the outlet of the cell growth chamber. In various embodiments, the hollow fibers can be made of a plastic adhesive material that can bind to certain cells, such as adherent stem cells. In various other embodiments, hollow fibers can be treated with a compound, such as fibronectin, to form an adhesive surface.

[0131] In some embodiments, the hollow fibers may be made of semi-permeable biocompatible polymeric materials. One such polymeric material that may be used is a blend of polyamide, polyarylethersulfone, and polyvinylpyrrolidone ("PA / PAES / PVP"). The semi-permeable membrane allows the movement of nutrients, waste products, and dissolved gases through the membrane between the EC and IC spaces. In various embodiments, the molecular transport characteristics of the hollow fiber membrane are selected to minimize the loss of expensive reagents required for cell growth (e.g., growth factors, cytokines, etc.) from the hollow fiber while allowing metabolic waste products to diffuse through the membrane into the hollow fiber lumen.

[0132] In one variation, one outer layer of each PA / PAES / PVP hollow fiber is characterized by a homogenous, open pore structure with a predetermined surface roughness, the pore openings being in the size range of 0.5-3 μm, and the number of pores on the outer surface of the fiber being within 1 mm 2 The number of pores is in the range of 10,000 to 150,000 per hollow fiber. This outer layer has a thickness of about 1 to 10 μm. The next layer in each hollow fiber is a second layer having the shape of a sponge structure, which in a further embodiment is about 1 to 15 μm thick. This second layer serves as a support for the outer layer. The third layer following the second layer has the shape of a finger-like structure. This third layer provides mechanical stability and a high void volume, giving the membrane a very low resistance to the transport of molecules through the membrane. In use, the finger-like voids are filled with a fluid, which gives the fluid a lower resistance to diffusion and convection than a matrix with a sponge-filled structure with a lower void volume. This third layer has a thickness of 20 to 60 μm.

[0133] In further embodiments, the hollow fiber membrane may comprise 65-95% by weight of at least one hydrophobic polymer and 5-35% by weight of at least one hydrophilic polymer. The hydrophobic polymer may be selected from the group consisting of polyamide (PA), polyaramid (PAA), polyarylethersulfone (PAES), polyethersulfone (PES), polysulfone (PSU), polyarylsulfone (PASU), polycarbonate (PC), polyether, polyurethane (PUR), polyetherimide, and copolymer mixtures of any of the above polymers (e.g., polyethersulfone, or mixtures of polyarylethersulfone and polyamide). In further embodiments, the hydrophilic polymer may be selected from the group consisting of polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polyglycol monoesters, water soluble cellulosic derivatives, polysorbates, and polyethylene-polypropylene oxide copolymers.

[0134] Depending on the type of cells being expanded in the cell growth chamber, the polymer fibers may be treated with substances such as fibronectin to enhance cell growth and / or attachment of the cells to the membrane.

[0135] US Patent Application Publication No. 2008 / 0220523 and US Patent Application Publication No. 2008 / 0248572 also have other detailed reactor embodiment examples, including detailed flow chart protocols. These various embodiments can be found, for example, in Figures 1B, 1C and 1D of US Patent Application Publication No. 2008 / 0220523. Said flow chart protocol is related to Figure 1D. Any of these are suitable for carrying out the present invention. See also the embodiments disclosed in US Patent Application Publication No. 2008 / 0220522. All of this text is incorporated by reference for the disclosure of these embodiments with respect to use in cells according to the present invention.

[0136] WO 2010 / 034468 provides another exemplary device comprising two compartments (a first internal compartment fitted with two accesses and a second external compartment fitted with one or two accesses) mounted in a casing and separated by a semipermeable membrane, both compartments also separated by an embedding compound based on a suitable attachment compound, intended to form, where applicable, (i) a cylindrical partition separating both compartments of said device comprising a semipermeable membrane of hollow fiber bundle type as defined above, or (ii) a seal in said device comprising a semipermeable membrane of sheet membrane type as defined above.

[0137] Another exemplary device includes a plurality of hollow fiber membranes contained within an outer shell and configured such that fluids in the space external to the hollow fibers (i.e., the outer capillary section) are separated from fluids passing through the hollow fibers and their corresponding orifices. Additionally, the device includes two manifold end chambers within the outer shell on opposite ends of the device. Each of the two orifices of the hollow fibers connects to another end chamber. The end chambers and the outer capillary section are separated by semipermeable membranes of the hollow fibers. The composition within the outer capillary section can be controlled to some extent by the molecular weight cutoff or pore size of the hollow fiber membranes.

[0138] In one mode of operating the device, cells are grown in the extracapillary compartment while nutrient medium is passed through the hollow fibers. In another mode of operating the device, cells are grown in the intracapillary space (i.e., lumen) of the hollow fibers while nutrient medium is passed through the extracapillary and / or intracapillary compartments. The semi-permeable properties of the hollow fibers allow nutrients and cellular waste products to pass through the hollow fiber walls while preventing cells from passing through the hollow fiber walls.

[0139] Shell-and-tube bioreactors offer several advantages. For adherent cells, the use of several hollow fibers provides a large surface area on which cells can grow within a relatively small volume. This large surface area also facilitates localized distribution of nutrient medium to the growing cells and rapid collection of cellular waste products. Shell-and-tube bioreactors allow cell growth at much higher densities than are possible with other cell culture devices. The bioreactor can grow cells at up to 10 cells per milliliter. 8 They can support cell densities greater than 10 cells per milliliter, whereas other cell culture devices typically support cell densities of approximately 10 cells per milliliter. 6 The density of individual cells is the limit.

[0140] stem cells The present invention may be preferably practiced using stem cells from vertebrate species, such as humans, non-human primates, domestic animals, livestock and other non-human mammals, including, but not limited to, those cells described below.

[0141] embryonic stem cells The most well-studied stem cells are embryonic stem cells (ESCs), because ESCs have unlimited self-renewal and multipotent differentiation potential. These cells can be derived from the inner cell mass of the blastocyst or from the primordial germ cells (embryonic germ cells or EG cells) of post-implantation embryos. ES and EG cells were first derived from mice and later from many different animals, and more recently from non-human primates and humans. When introduced into mouse blastocysts or blastocysts of other animals, ESCs can contribute to all tissues of the animal. ES and EG cells can be identified by positive staining with antibodies against SSEA1 (mouse) and SSEA4 (human). See, for example, U.S. Patent Nos. 5,453,357; 5,656,479; 5,670,372; 5,843,780; 5,874,301; 5,914,268; 6,110,739; 6,190,910; 6,200,806; 6,432,711; 6,436,701, 6,500,668; 6,703,279; 6,875,607; 7,029,913; 7,112,437; 7,145,057; 7,153,684; and 7,294,508. Each of these references is incorporated by reference for its teaching of embryonic stem cells and methods for their production and expansion. Accordingly, ESCs and methods for their isolation and expansion are well known in the art.

[0142] Numerous transcription factors and exogenous cytokines have been identified that affect the pluripotent state of embryonic stem cells in vivo. The first transcription factor described that is involved in stem cell pluripotency is Oct4. Oct4 belongs to the POU (Pit-Oct-Unc) family of transcription factors and is a DNA-binding protein that can activate the transcription of genes that contain an octamer sequence, called the "octamer motif," in their promoter or enhancer regions. Oct4 is expressed during the cleavage stage of fertilized zygotes until the formation of the egg cylinder. The function of Oct3 / 4 is to repress differentiation-inducing genes (i.e., FoxaD3, hCG) and to activate pluripotency-promoting genes (FGF4, Utfl, Rex1). Sox2, a member of the high mobility group (HMG) box transcription factors, cooperates with Oct4 to activate the transcription of genes expressed in the inner cell mass. It is essential that Oct3 / 4 expression in embryonic stem cells is maintained between specific levels. Overexpression or downregulation of Oct4 expression levels by more than 50% would alter embryonic stem cell fate towards primitive endoderm / mesoderm or trophectoderm, respectively. In vivo, Oct4-deficient embryos develop to the blastocyst stage, but cells of the inner cell mass are not pluripotent. Instead, Oct4-deficient embryos differentiate along the extraembryonic trophoblast lineage. The mammalian Spalt transcription factor, Sall4, is an upstream regulator of Oct4 and is therefore important for maintaining appropriate levels of Oct4 during early stages of development. When Sall4 levels fall below a certain threshold, trophectoderm cells ectopically amplify and enter into the inner cell mass. Another transcription factor required for pluripotency is Nanog, named after the Celtic "Tir na nOg": paradise of ever-young people. In vivo, Nanog is expressed from the late compacted morula stage, then restricted to the inner cell mass and downregulated by implantation. Downregulation of Nanog may be important to prevent uncontrolled expansion of pluripotent cells and allow multilineage differentiation during gastrulation. Nanog null embryos isolated at day 5.5 consist of disorganized blastocysts containing mainly extraembryonic endoderm and no discernible epiblast.

[0143] non-embryonic stem cells Stem cells have been identified in most tissues. Perhaps the best characterized are hematopoietic stem cells (HSCs). HSCs are mesodermally derived cells that can be purified using cell surface markers and functional characteristics. HSCs have been isolated from bone marrow, peripheral blood, umbilical cord blood, fetal liver, and yolk sac. HSCs initiate hematopoiesis and give rise to multiple hematopoietic lineages. When transplanted into lethally irradiated animals, HSCs can repopulate the erythroid neutrophil-macrophage, megakaryocyte, and lymphoid hematopoietic cell pools. HSCs can also be induced to undergo some self-renewal cell divisions. See, e.g., U.S. Pat. Nos. 5,635,387; 5,460,964; 5,677,136; 5,750,397; 5,681,599; and 5,716,827. U.S. Patent No. 5,192,553 reports a method for isolating human neonatal or fetal hematopoietic stem or progenitor cells. + Human hematopoietic cells, which are precursor cells, and suitable growth media for regenerating them in vitro have been reported. US Patent No. 5,635,387 reports a method and device for culturing human hematopoietic cells and their precursors. US Patent No. 6,015,554 describes a method for reconstituting human lymphocytes and dendritic cells. Thus, HSCs and methods for their isolation and expansion are well known in the art.

[0144] Another stem cell known in the art is the neural stem cell (NSC). These cells can proliferate in vivo and continually regenerate at least some neuronal cells. When cultured in vivo, neural stem cells can be induced to proliferate and differentiate into various types of neurons and glial cells. When transplanted into the brain, neural stem cells can engraft and give rise to neural and glial cells. See, for example, Gage FH, Science, 287:1433-1438 (2000); Svendsen SN et al., Brain Pathology, 9:499-513 (1999); and Okabe S. et al., Mech Development, 59:89-102 (1996). U.S. Patent No. 5,851,832 reports multipotent neural stem cells obtained from brain tissue. U.S. Patent No. 5,766,948 reports the production of neuroblasts from neonatal brain hemispheres. U.S. Patent No. 5,564,183 and U.S. Patent No. 5,849,553 report the use of mammalian neural crest stem cells. US Patent No. 6,040,180 reports the in vitro generation of differentiated neurons from the culture of mammalian pluripotent CNS stem cells. WO 98 / 50526 and WO 99 / 01159 report the generation and isolation of neuroepithelial stem cells, oligodendrocyte-astrocyte precursors and lineage-committed neuronal precursors. US Patent No. 5,968,829 reports neural stem cells obtained from embryonic forebrain. Thus, neural stem cells and methods for their production and expansion are well known in the art.

[0145] Another stem cell that has been widely studied in the field is the mesenchymal stem cell (MSC). MSCs are derived from embryonic mesoderm and can be isolated from numerous sources, including adult bone marrow, peripheral blood, fat, placenta and umbilical cord blood, among others. MSCs can differentiate into many mesodermal tissues, including muscle, bone, cartilage, fat and tendon. There is a considerable literature on these cells. See, for example, U.S. Patent No. 5,486,389; U.S. Patent No. 5,827,735; U.S. Patent No. 5,811,094; U.S. Patent No. 5,736,396; U.S. Patent No. 5,837,539; U.S. Patent No. 5,837,670; and U.S. Patent No. 5,827,740. See also Pittenger, M. et al., Science, 284:143-147 (1999).

[0146] Another example of adult stem cells is adipose-derived adult stem cells (ADSCs), which are typically isolated from adipose by liposuction and then releasing ADSCs using collagenase. ADSCs are similar in many ways to bone marrow-derived MSCs, except that much more cells can be isolated from adipose. These cells have been reported to differentiate into bone, fat, muscle, cartilage and neurons. Isolation methods are described in US Patent Application Publication No. 2005 / 0153442.

[0147] Other stem cells known in the art include gastrointestinal stem cells, also known as "oval cells," epithelial stem cells, and hepatic stem cells (Potten, C., et al., Trans R Soc Lond B Biol Sci, 353:821-830 (1998); Watt, F., Trans R Soc Lond B Biol Sci, 353:831 (1997); Alison et al., Hepatology, 29:678-683 (1998)).

[0148] Other non-embryonic cells that have been reported to be capable of differentiating into cell types of more than one embryonic germ layer include cells from umbilical cord blood (see U.S. Patent Application Publication No. 2002 / 0164794), placenta (see U.S. Patent Application Publication No. 2003 / 0181269), umbilical cord matrix (Mitchell, K. E. et al., Stem Cells, 21:50-60 (2003)), small embryonic-like stem cells (Kucia, M. et al., J Physiol Pharmacol, 57 Suppl 5:5-18 (2006)), amniotic fluid stem cells (Atala, A., J Tissue Regen Med, 1:83-96 (2007)), skin-derived progenitors (Toma et al., Nat Cell 2007, 1:83-96 (2007)), and oocyte-derived progenitors (Toma et al., Nat Cell 2007, 1:83-96 (2007)). Biol, 3:778-784 (2001)) and bone marrow (see U.S. Patent Application Publication Nos. 2003 / 0059414 and 2006 / 0147246), each of which is incorporated by reference for the teachings of these cells.

[0149] Strategies to reprogram somatic cells Several different strategies, such as nuclear transfer, cell fusion and culture-induced reprogramming, have been used to induce the conversion of differentiated cells to an embryonic state. Nuclear transfer involves the injection of a somatic cell nucleus into an enucleated oocyte, which can give rise to a clone when transferred into a surrogate mother ("germline cloning") or to a genetically matched embryonic stem (ES) cell when explanted in culture ("somatic cell nuclear transfer", SCNT). Cell fusion between somatic and ES cells results in the creation of hybrids that exhibit all the properties of pluripotent ES cells. Explantation of somatic cells in culture selects for immortal cell lines that can be pluripotent or multipotent. Currently, spermatogonial stem cells are the only source of pluripotent cells that can be derived from postnatal animals. Transduction of somatic cells with certain factors can initiate reprogramming to a pluripotent state. These experimental approaches have been extensively reviewed (Hochedlinger and Jaenisch, Nature, 441:1061-1067 (2006) and Yamanaka, S., Cell Stem Cell, 1:39-49 (2007)).

[0150] nuclear transfer Nuclear transfer (NT), also called somatic cell nuclear transfer (SCNT), refers to the introduction of a nucleus from a donor somatic cell into an enucleated oocyte to generate a cloned animal (e.g., Dolly the sheep) (Wilmut et al., Nature, 385:810-813 (1997)). The generation of live animals by NT has demonstrated that the epigenetic state of somatic cells, including that of terminally differentiated cells, is stable, but not irreversibly fixed, and can be reprogrammed to an embryonic state capable of directing the development of new organismal organs. In addition to providing an exciting experimental endeavor for elucidating fundamental epigenetic mechanisms involved in embryonic development and disease, nuclear cloning techniques are of potential interest for patient-specific transplantation medicine.

[0151] Fusion of somatic cells and embryonic stem cells Epigenetic reprogramming of somatic nuclei to an undifferentiated state has been demonstrated in mouse hybrids generated by fusion of embryonic and somatic cells. Hybrids between various somatic cells and embryonic carcinoma cells (Solter, D., Nat Rev Genet, 7:319-327 (2006)), embryonic germ (EG) cells or ES cells (Zwaka and Thomson, Development, 132:227-233 (2005)) share many properties with the parental embryonic cells, indicating that a pluripotent phenotype predominates in such fusion products. As with mice (Tada et al., Curr Biol, 11:1553-1558 (2001)), human ES cells have the potential to reprogram somatic cell nuclei after fusion (Cowan et al., Science, 309:1369-1373 (2005); Yu et al., Science, 318:1917-1920 (2006)). Activation of silent pluripotency markers (e.g., Oct4) or reactivation of the inactive somatic X chromosome provided molecular evidence for reprogramming of the somatic genome in the hybrid cells. It has been suggested that DNA replication is essential for the activation of pluripotency markers that are first observed two days after fusion (Do and Scholer, Stem Cells, 22:941-949 (2004)), and that forced overexpression of Nanog in ES cells promotes pluripotency when fused with neural stem cells (Silva et al., Nature, 441:997-1001 (2006)).

[0152] Culture-induced reprogramming Pluripotent cells have been derived from embryonic sources, e.g., the inner cell mass (ICM) of blastomeres and blastocysts (ES cells), epiblast (EpiSC cells), primordial germ cells (EG cells) and postnatal spermatogonial stem cells ("maGSCsm", "ES-like" cells).The following pluripotent cells, along with their donor cells / tissues, are: parthogenetic ES cells are derived from mouse oocytes (Narasimha et al., Curr Biol, 7:881-884 (1997)); embryonic stem cells are derived from blastomeres (Wakayama et al., Stem Cells, 25:986-993 (2007)); inner cell mass cells (source not applicable) (Eggan et al., Nature, 428:44-49 (2004)); embryonic germ cells and embryonic carcinoma cells are derived from primordial germ cells (Matsui et al., Cell, 70:841-847 (1992)); GMCS, maSSC and MASC are derived from spermatogonial stem cells (Guan et al., Nature, 440:1199-1203 (2006); Kanatsu-Shinohara et al., Cell, 119: 1001-1012 (2004); and Seandel et al., Nature, 449:346-350 (2007); EpiSC cells have been derived from the epiblast (Brons et al., Nature, 448:191-195 (2007); Tesar et al., Nature, 448:196-199 (2007)); parthogenetic ES cells have been derived from human oocytes (Cibelli et al., Science, 295L819 (2002); Revazova et al., Cloning Stem Cells, 9:432-449 (2007)); human ES cells have been derived from human blastocysts (Thomson et al., Science, 282:1145-1147 (1998)); MAPCs have been derived from bone marrow (Jiang et al., Nature, 418:41-49 (2002); Phinney and Prockop, Stem Cells, 25:2896-2902 (2007)); umbilical cord blood cells (derived from umbilical cord blood) (van de Ven et al., Exp Hematol, 35:1753-1765 (2007)); neurosphere-derived cells derived from neural cells (Clarke et al., Science, 288:1660-1663 (2000)).Donor cells from germ cell lineages, such as PGCs or spermatogonial stem cells, are known to be unipotent in vivo, but it has been shown that pluripotent ES-like cells (Kanatsu-Shinohara et al., Cell, 119:1001-1012 (2004)) or maGSCs (Guan et al., Nature, 440:1199-1203 (2006)) can be isolated after long-term in vitro culture. Most of these pluripotent cell types are capable of differentiation and teratoma formation in vitro, whereas only maGSCs or ES-like cells derived from ES, EG, EC and spermatogonial stem cells were pluripotent even by more stringent criteria, because they were able to form postnatal chimeras and contribute to the germ cell lineage. Recently, multipotent adult spermatogonial stem cells (MASCs) have been derived from testicular spermatogonial stem cells in adult mice; these cells have an expression profile distinct from that of ES cells (Seandel et al., Nature, 449:346-350 (2007)), but similar to EpiSC cells derived from the epiblast of postimplantation mouse embryos (Brons et al., Nature, 448:191-195 (2007); Tesar et al., Nature, 448:196-199 (2007)).

[0153] Reprogramming by defined transcription factors Takahashi and Yamanaka reported reprogramming somatic cells back to an ES-like state (Takahashi and Yamanaka, Cell, 126:663-676 (2006)). They successfully reprogrammed mouse embryonic fibroblasts (MEFs) and adult fibroblasts into pluripotent ES-like cells after viral-mediated transduction of four transcription factors (Oct4, Sox2, c-myc, and Klf4) followed by selection for activation of Fbx15 (Figure 2A), a target gene of Oct4. Cells with activated Fbx15 were made into iPS (induced pluripotent stem) cells and shown to be pluripotent by their ability to form teratomas, but failed to give rise to viable chimeras. This pluripotent state was dependent on continuous viral expression of the transduced Oct4 and Sox2 genes. On the other hand, the endogenous Oct4 and Nanog genes were either not expressed or expressed at a lower level than in ES cells, and their respective promoters were found to be largely methylated. This is consistent with the conclusion that Fbx15-iPS cells did not represent ES cells, but may represent an incomplete state of reprogramming. Although genetic experiments have established that Oct4 and Sox2 are essential for pluripotency (Chambers and Smith, Oncogene, 23:7150-7160 (2004); Ivanona et al., Nature, 442:533-538 (2006); Masui et al., Nat Cell Biol, 9:625-635 (2007)), the role of two oncogenes, c-myc and Klf4, in reprogramming is less clear. Some of these oncogenes may not actually be essential for reprogramming, since both mouse and human iPS cells have been derived without c-myc transduction, albeit at low efficiency (Nakagawa et al., Nat Biotechnol, 26:191-106 (2008); Werning et al., Nature, 448:318-324 (2008); Yu et al., Science, 318:1917-1920 (2007)).

[0154] MAPC Human MAPC is described in U.S. Patent No. 7,015,037. MAPC has been identified in other mammals. Murine MAPC is also described, for example, in U.S. Patent No. 7,015,037. Rat MAPC is also described in U.S. Patent No. 7,838,289.

[0155] These references are incorporated by reference for their description of MAPC first isolated by Catherine Verfaillie.

[0156] Isolation and expansion of MAPCs Methods for isolating MAPCs are known in the art. See, for example, U.S. Patent No. 7,015,037. These methods, together with the characterization (phenotype) of MAPCs, are incorporated herein by reference. MAPCs can be isolated from multiple sources, including, but not limited to, bone marrow, placenta, umbilical cord and umbilical cord blood, muscle, brain, liver, spinal cord, blood or skin. Thus, bone marrow aspirates, brain or liver biopsies, and other organs can be obtained and, depending on the genes expressed (or not expressed) in these cells, the cells can be isolated using positive or negative selection techniques available to those skilled in the art (e.g., by functional or morphological assays, such as those disclosed in the above-referenced applications, which are incorporated herein by reference).

[0157] MAPCs have also been obtained by modified versions of the methods described in Breyer et al., Experimental Hematology, 34:1596-1601 (2006) and Subramanian et al., Cellular Programming and Reprogramming: Methods and Protocols; S. Ding (ed), Methods in Molecular Biology, 636:55-78 (2010), which are incorporated by reference for these methods.

[0158] Human bone marrow-derived MAPCs as described in U.S. Pat. No. 7,015,037 MAPCs express neither the common leukocyte antigen CD45 nor the erythroblast-specific glycophorin-A (Gly-A). The mixed population of cells was subjected to Ficoll Hypaque separation. The cells were then subjected to negative selection using anti-CD45 and anti-Gly-A antibodies to remove CD45. + and Gly-A + The cell population was depleted and the remaining approximately 0.1% of bone marrow mononuclear cells were then harvested. Cells were also plated onto fibronectin-coated wells and cultured for 2–4 weeks as described below to identify CD45 + and Gly-A + In cultures of adherent bone marrow cells, many adherent stromal cells undergo replicative senescence at approximately cell doubling 30, and a more homogenous population of cells continues to expand and maintains long telomeres.

[0159] Alternatively, positive selection can be used to isolate cells by a combination of cell-specific markers. Both positive and negative selection techniques are available to those of skill in the art, and many monoclonal and polyclonal antibodies suitable for negative selection purposes are also available in the art (see, e.g., Leukocyte Typing V, Schlossman et al., Eds. (1995) Oxford University Press) and commercially available from a number of sources.

[0160] Techniques for separating mammalian cells from mixtures of cell populations have also been described by Schwartz et al. in U.S. Pat. No. 5,759,793 (magnetic separation), by Basch et al. in 1983 (immunoaffinity chromatography), and by Wysocki and Sato in 1978 (fluorescence-activated cell sorting).

[0161] Cells may be cultured in low serum or serum-free culture medium. Serum-free medium used to culture MAPCs is described in U.S. Patent No. 7,015,037. Commonly used growth factors include, but are not limited to, platelet-derived growth factor and epidermal growth factor. See, for example, U.S. Patent No. 7,169,610; U.S. Patent No. 7,109,032; U.S. Patent No. 7,037,721; U.S. Patent No. 6,617,161; U.S. Patent No. 6,617,159; U.S. Patent No. 6,372,210; U.S. Patent No. 6,224,860; U.S. Patent No. 6,037,174; U.S. Patent No. 5,908,782; U.S. Patent No. 5,766,951; U.S. Patent No. 5,397,706; and U.S. Patent No. 4,657,866. All are incorporated by reference for growing cells in serum-free medium.

[0162] Further culture methods In further experiments, MAPCs were cultured at a density of approximately 100 cells / cm. 2 or approximately 150 cells / cm 2 ~about 10,000 cells / cm 2 (about 200 cells / cm 2 ~about 1500 cells / cm 2 ~about 2000 cells / cm 2 The density may vary between species. Additionally, the optimal density may vary depending on the culture conditions and the source of the cells. It is within the skill of the art to determine the optimal density for a given set of culture conditions and cells.

[0163] Additionally, effective atmospheric oxygen concentrations of less than about 10%, including about 1-5%, and especially 3-5%, may be used at any point during isolation, expansion and differentiation of MAPCs in culture.

[0164] The cells may be cultured under various serum concentrations (e.g., about 2-20%). Fetal bovine serum may be used. Higher concentrations of serum (e.g., about 15-20%) may be used in combination with lower oxygen tension. The cells do not need to be selected before attachment to the culture dish. For example, after a Ficoll gradient, the cells may be cultured at, for example, 250,000-500,000 cells / cm. 2 Adherent colonies can be picked, possibly pooled, and amplified.

[0165] In one embodiment used in the experimental procedures in the Examples, high serum (approximately 15-20%) and low oxygen (approximately 3-5%) conditions were used for the cell culture. Specifically, adherent cells from colonies were cultured at approximately 1700-2300 cells / cm. 2 The cells are plated and passaged at a density of 100x in 18% serum and 3% oxygen (containing PDGF and EGF).

[0166] In embodiments specific for MAPCs, the supplement is a cellular factor or component that allows MAPCs to retain the ability to differentiate into cell types of more than one embryonic lineage (e.g., all three lineages), which may be indicated by expression of specific markers of the undifferentiated state (e.g., Oct3 / 4 (Oct3A)) and / or markers of high expression potential (e.g., telomerase).

[0167] cell culture For all of the above ingredients listed below, see US Pat. No. 7,015,037, which is incorporated by reference for the teachings of these ingredients.

[0168] Generally, the cells useful in the present invention can be maintained and expanded in culture media available and well known in the art. The addition of cell culture medium with mammalian serum is contemplated. Additional supplements can also be advantageously used to supply cells with essential trace elements for optimal growth and expansion. Hormones can also be advantageously used in cell culture. Lipids and lipid carriers can also be used to supplement cell culture medium depending on the cell type and the fate of the differentiated cells. The use of feeder cell layers is also contemplated.

[0169] Stem cells often require additional factors (e.g., laminin, type I and type II collagen, chondroitin sulfate, fibronectin, "superfibronectin" and fibronectin-like polymers, gelatin, poly-D and poly-L-lysine, thrombospondin and vitronectin) that promote their attachment to solid supports. Other suitable coating materials based on or composed of basement membrane-derived protein mixtures can be used. Some of these are commercially available, e.g., Matrigel. Coatings can use extracellular matrix proteins and their suitable derivatives, as well as mixtures of these proteins. In one embodiment of the present invention, fibronectin is used. See, e.g., Ohashi et al., Nature Medicine, 13:880-885 (2007); Matsumoto et al., J Bioscience and Bioengineering, 105:350-354 (2008); Kirouac et al., Cell Stem Cell, 3:369-381 (2008); Chua et al., Biomaterials, 26:2537-2547 (2005); Drobinskaya et al., Stem Cells, 26:2245-2256 (2008); Dvir-Ginzberg et al., FASEB J, 22:1440-1449 (2008); Turner et al., J Biomed Mater Res Part B:Appl Biomater, 82B:156-168 (2007); and Miyazawa et al., Journal of Gastroenterology and See Hepatology, 22:1959-1964 (2007).

[0170] Once established in culture, the cells may be used fresh or frozen and stored as frozen stocks using, for example, DMEM containing 20%-40% FCS and 10% DMSO. In one embodiment, 20% FCS is used. Other methods for preparing frozen stocks for cultured cells are available to one of skill in the art.

[0171] For the purposes of this application, the further and other culture methods also apply to the bioreactor method with respect to the above medium components and conditions. As an example, in the illustrated embodiment, the oxygen concentration is 5%, serum is about 19%, and both EGF and PDGF are added to the medium.

[0172] Pharmaceutical preparations No. 7,015,037 is incorporated by reference for its teaching of pharmaceutical formulations. In certain embodiments, the cell population is present within a composition that is adapted and suitable for delivery (i.e., physiologically compatible).

[0173] In some embodiments, the purity of the cells (or conditioned medium) for administration to a subject is about 100% (substantially homogeneous). In other embodiments, the purity is 95%-100%. In some embodiments, the purity is 85%-95%. In particular, in the case of a mixture with other cells, the percentage can be about 10%-15%, 15%-20%, 20%-25%, 25%-30%, 30%-35%, 35%-40%, 40%-45%, 45%-50%, 60%-70%, 70%-80%, 80%-90%, or 90%-95%. Alternatively, isolation / purity can be expressed in terms of cell doublings, where the cells have undergone, for example, 10-20, 20-30, 30-40, 40-50, or more cell doublings.

[0174] The choice of formulation for administering the cells for a given application depends on a variety of factors. Prominent among these are the species of the subject, the nature of the condition to be treated, its condition and distribution in the subject, the nature of other treatments and drugs being administered, the optimal route for administration, viability via said route, administration regimen, and other factors that will be apparent to those skilled in the art. For example, the selection of suitable carriers and other additives will depend on the exact route of administration and the nature of the specific administration form.

[0175] Final formulation of the cells / medium in an aqueous suspension typically includes adjusting the ionic strength of the suspension to isotonicity (i.e., about 0.1 to 0.2) and physiological pH (i.e., about pH 6.8 to 7.5). The final formulation typically also includes a fluid lubricant.

[0176] In some embodiments, the cells / culture medium are formulated into a unit dose injectable form (e.g., solution, suspension or emulsion). The pharmaceutical preparation suitable for injection of cells / culture medium is typically a sterile aqueous solution and dispersion. The carrier for injectable preparation can be a solvent or dispersion medium, including, for example, water, saline, phosphate buffered saline, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), and suitable mixtures thereof.

[0177] One skilled in the art can readily determine the amount of cells, and optional additives, vehicles and / or carriers, in the composition administered in the method of the present invention. Typically, any additives (in addition to the cells) are present in a solution (e.g., phosphate buffered saline) in an amount of 0.001 to 50 wt%. The active ingredient is present in an amount on the order of micrograms to milligrams, for example, about 0.0001 to about 5 wt%, preferably about 0.0001 to about 1 wt%, most preferably about 0.0001 to about 0.05 wt%, or about 0.001 to about 20 wt%, preferably about 0.01 to about 10 wt%, and most preferably about 0.05 to about 5 wt%. EXAMPLES

[0178] Example 1: Amplification of MultiStem from a cell bank using a hollow fiber bioreactor cell amplification system A cell amplification system essentially as described in US Patent Application Publication No. 2008 / 0220523 and Antwiler et al. was used to amplify the input population of MultiStem. MultiStem is a substantially homogenous population. The system was named Quantum CES. Quantum CES provided a benchtop amplification system that is particularly useful for autologous amplification (although Quantum CES is also useful for allogeneic amplification). Based on the results presented herein, it is believed that 10 8 More than one cell may be obtained from a single donor.

[0179] Multi-Stem was stored in a frozen cell bank and then thawed. For two experiments, 10 × 10 6 Each MultiStem had an internal fluid volume of 184 ml and an external fluid volume of 303 ml, with a total surface area (within the capillaries) of approximately 2.1 m 2 (3255in 2 ), with a wall thickness of 50 μm, an inner diameter of 215 μm, and a total length of 295 mm (average 30 mm per fiber, range 10–50 mm), of 1.1 × 10 4 The cells were inoculated into a continuous flow bioreactor containing 1000 cells of hollow fibers. The pore size had an approximate cutoff of 16 kDa. The cells attached to the inside of the hollow fibers. The cells were cultured for 6 days. 752 x 10 6 pieces, 753×10 6 pcs and 782×10 6 Cells were generated in three independent experiments starting from the same seeding stock.

[0180] The flow rate could be varied, but was generally increased as the cells grew to provide sufficient nutrients and remove sufficient waste products. Typically, the flow rate could be increased by approximately 10-fold. However, this parameter was adjusted by monitoring the levels of the waste products (e.g., lactate) and glucose in the medium.

[0181] The wall material was a composite of PA / PAES / PVP.

[0182] Also, in this particular embodiment, the fibers are coated with fibronectin.

[0183] For established cells, i.e. derived from previously isolated, amplified and substantially purified cultures, 5 mg of fibronectin is used and coated overnight. The coating is then washed off and replaced by medium. After seeding, the cells are allowed to attach for 24 hours without flow through the intracellular loop. The feed rate is then started at about 0.1 ml per minute. Based on lactate levels and the doubling rate of the cells, the feed rate is doubled approximately every 24 hours. During the first three days, we attempt to maintain lactate levels at approximately 0.5 g / l. During the last three days, the lactate is maintained at approximately 1 g / l, with a maximum of 1.5 g / l. On the last day (i.e. when the cells are maximally amplified), the feed rate is approximately 3 ml / min.

[0184] Cells are harvested using approximately 200 ml of 2.5% trypsin, with an incubation period of 2.5 minutes and a harvest volume of approximately 500 ml.

[0185] When using bone marrow aspirate, the capillary inner surface is coated with about 10 mg of fibronectin during the 48 hour attachment phase. The feed rate is adjusted so that it doubles when the lactate level rises to 0.4-0.5 g / l. The rate is generally not high compared to cultures starting from established cells. In one experiment, about 25-30 ml of bone marrow aspirate is cultured from total BMMCs, with approximately 4 x 10 6 For this purpose, bone marrow was subjected to a ficoll gradient to remove non-nucleated cells.

[0186] Details can be found in Figure 5. The flow scheme includes two loops: intracapillary (IC) and extracapillary (EC). The IC loop has three inlet lines: a cell line, a reagent line and an IC medium line. Bags are attached to these lines to add cells, coating agents, trypsin and medium. Each line is controlled by a valve. The valves have two positions: open or closed. The inlet rate is controlled by an IC inlet pump (1). The circulation in the system is controlled by an IC circulation pump (2). The IC circuit includes 150 ml. The EC loop has two inlet lines: a wash (solution) line and an EC medium line. Bags are attached to these lines to wash with PBS and to add medium to the EC loop. The EC inlet rate is controlled by an EC inlet pump (3). The circulation in this circuit is controlled by an EC circulation pump (4). An oxygenator is present in the EC loop. The oxygenator is attached to an external gas cylinder (for MultiStem this is 90% N2; 5% O2; 5% CO2) to maintain gas concentrations for the EC medium. The IC medium is equilibrated by perfusion of gas through a membrane in the bioreactor. The EC circuit contains approximately 250 ml. There are two means of removing solution / cells from the system: a waste bag or a collection bag. The IC and EC loops have connections to the waste bag, controlled by valves. The collection bag is only connected to the IC loop, also controlled by a valve.

[0187] The input population was compared to the output population. Specifically, the input population was evaluated for gene expression of specific selected genes and compared to the output population. Additionally, morphology and ploidy were compared. The output population was substantially identical to the input population with respect to the parameters measured.

[0188] Example 2: Production of bone marrow-derived MultiStem in a hollow fiber bioreactor cell expansion system The cell amplification system described above was used to produce MultiStem from bone marrow mononuclear cells. The amplification results are shown in FIG. 6. In one possible regimen, a MultiStem master cell bank can be generated within 17 days starting from a bone marrow aspirate. This requires one run from bone marrow to 15 population doublings and an amplification run until the collection achieves 18.5 population doublings, and an average of 10 runs to generate a master cell bank (200 vials of 20 million cells). These 200 vials can then be used to generate a working cell bank. A schematic of this is shown in FIG. 7. However, the master cell bank can be expanded or contracted, for example, to 10-fold more or 10-fold fewer cells.

[0189] The output cells, after expansion, possessed the immunomodulatory properties associated with MultiStem and expressed telomerase.

Claims

[Claim 1] The present invention relates to amplifying the cells described herein in a hollow fiber bioreactor.

Citation Information

Patent Citations

  • Method for culturing mesenchymal stem cells

    JP2009540865A

  • Cell proliferation system and method of use

    JP2010519937A

  • Improved bioreactor surface

    JP2010523118A

  • In situ bioreactors and methods of use thereof

    US20010044413A1

  • Methods of culturing, storing, and inducing differentiation in cells, instrument for use in the methods, method of using the instrument, and medicial biomaterial

    US20030224510A1